|
Human RBC alloimmunization evaluation after exposure to foreign E antigen of the rhesus system in transfusion |
|
View Full Text View/Add Comment Download reader |
DOI:10.46701/APJBG.20170116009 |
KeyWord:RBC alloimmunization, anti-E alloantibody, RBC transfusion |
Author | Institution |
Pu Xu |
Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
Yan Li |
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
Su Zhou |
Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
Ziqi He |
Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
You Yang |
Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
Hua Yu |
Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China. |
|
Hits: 2905 |
Download times: 2453 |
Abstract: |
Anti-E alloantibody has been one of the most frequently detected clinically significant alloantibodies in previous studies. Red blood cell (RBC) transfusion is unique in its common intravenous introduction of foreign E antigen and provides a valuable opportunity to study the human immunologic response to intravenous foreign E antigen. Patients exposed to foreign E antigen while receiving RBC transfusions are at risk of forming anti-E alloantibody. Valid estimates of anti-E alloimmunization risk are clinically important, but the forming mechanism of anti-E alloimmunization remains unclear. Here, we screened 516 inpatients at risk of exposure to foreign E antigen while receiving RBC transfusions and monitored the development of anti-E alloantibody for up to two years after left hospital. However, only 2 cases of anti-E alloimmunization were identified in this study. Patients who received RBC transfusion had a very high risk of exposure to foreign E antigen, but the anti-E alloantibody production incidence was very low and few anti-E alloantibodies were produced within 3 to 6 months after RBC transfusion in this study. Further research would contribute to our knowledge of the anti-E alloimmunization mechanism and prevent anti-E development, which would be significantly useful in clinical for transfusions, obstetric management, and the evaluation and management of transfusion reactions in laboratory and institutional resources and cost reduction in healthcare system. |
Close |
|
|
|